anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pancreaticoduodenectomy remains the treatment of choice for periampullary malignancies. Advances in pancreatic surgery techniques and perioperative care have led to reduced mortality rates for Pancreaticodudenectomy \[1\]. However, morbidity after pancreatic resection remains high, with 30-60% of patients experiencing complications following surgery, mainly as a result of leak and subsequent fistula from the pancreatic anastomosis \[2\].The leakage of the pancreatic anastomosis remains the most serious problem as it is the major cause of morbidity after pancreaticoduodenectomy, and also contributes significantly to prolonged hospitalization \[5\]. For this reason, surgeons have always directed their efforts at reducing the rate of pancreatic fistula through the introduction of new and effective methods of construction of the pancreatic anastomosis \[6\]. Various techniques have been described for joining the pancreatic stump either with the jejunum or with the stomach, with or without internal or external drainage of the pancreatic duct. Recently, new prospective randomized studies have demonstrated the advantage of pancreaticogastrostomy over pancreaticojejunostomy in reducing the incidence of pancreatic fistula \[3\]; however, none of these techniques has proved to be superior in minimizing postoperative mortality and morbidity \[4\]. One of the difficulties of pancreatic reconstruction after pancreaticoduodenectomy is the presence of soft pancreas which leads to high risk of fistula so dunking technique was raised \[8\]. But few researches or papers have focused on its efficacy and even fewer papers have discussed dunking in pancreaticogastrostomy and pancreaticojejunostomy, So this is the interest of our study to compare between the efficacies of these two techniques.
PROBLEM TO BE SOLVED: To obtain a compound capable of activating enzyme activity of cystathionine β-synthase (CBS). SOLUTION: This therapeutic agent for homosysteinemia or a psychotropic agent comprises a nitroprusside compound and/or its derivative as an active ingredient. The nitroprusside compound is capable of enhancing the enzyme activity of the CBS. As a result, homocysteine is consumed to reduce the homocysteine level in blood. The amelioration of the homosysteinemia is useful even for treatment of homocystinuria. Hydrogen sulfide produced by enzymic actions of the CBS acts as a neurotransmitter or a modifier in the brain. Thereby, the nitroprusside compound is useful even as the psychotropic agent.
Randomized Controlled Trials was used to collect data. Total patients were selected in two group with each 31 subjects. Purposive sampling technique was used. Experimental group will receive routine physical therapy along with TENS, Hot pack and Neurodynamic Stretching. (For 30 seconds, 3 times per session for 3 alternative days a week \& duration of 4 weeks). Outcome measure will be the hamstring tightness value angle in degrees, which will be obtained with the help of goniometer after performing active knee extension test and active straight leg raise test
The invention provides a medicine for treating common cold. The medicine is prepared by the use of only a chemical drug, which is diammonium glycyrrhizinate. It is shown through recent basic research that many symptoms of common cold are possibly induced body excessive inflammatory responses based on virus infection. diammonium glycyrrhizinate has a strong physiological and pharmacological effect of cortical hormone in human body. The body excessive inflammatory responses are inhibited through the effect, which is in allusion to the central link of common cold pathopoiesia. It is confirmed through a test that only the medicine diammonium glycyrrhizinate is needed to alleviate all the symptoms of common cold. In addition, it is safer for a patient to take one medicine. The production of the medicine is much simpler.
Osteoarthritis (OA) is a debilitating chronic degenerative disease affecting the whole joint organ leading to pain and disability. Cellular stress and injuries trigger inflammation and the onset of pathophysiological changes ensue after irreparable damage and inability to resolve inflammation, impeding the completion of the healing process. Extracellular matrix (ECM) degradation leads to dysregulated joint tissue metabolism. The reparative effort induces the proliferation of hypertrophic chondrocytes and matrix protein synthesis. Aberrant protein synthesis leads to endoplasmic reticulum (ER) stress and chondrocyte apoptosis with consequent cartilage matrix loss. These events in a vicious cycle perpetuate inflammation, hindering the restoration of normal tissue homeostasis. Recent evidence suggests that inflammatory responses and chondrocyte apoptosis could be caused by the activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signalling axis in response to DNA damage. It has been reported that there is a crosstalk between ER stress and cGAS-STING signalling in cellular senescence and other diseases. Based on recent evidence, this review discusses the role of ER stress, Unfolded Protein Response (UPR) and cGAS-STING pathway in mediating inflammatory responses in OA.
The invention provides a strain of human lactobacillus fermentum ZJUIDS06 and application thereof. The classification and the name are Lactobacillus fermentum, and the preservation number is CGMCC NO. 21339. The strain has functional lactic acid bacteria with better capability of reducing blood fat in vivo, and can obviously reduce serum total cholesterol, triglyceride and low-density lipoprotein cholesterol in an eight-week gastric lavage test of a hyperlipemia golden hamster model. The strain also has strong antioxidation and cholesterol reduction effects, good acid resistance and bile salt resistance, no antibiotic resistance of a culture solution, and inhibition of harmful pathogenic bacteria in intestines, and the strain is proved to have good probiotic characteristics. When the product is applied to the production of fermented egg yoghourt and Monterey cheese, the cholesterol content in the product can be obviously reduced, and the functional probiotic products with the functions of reducing blood fat, reducing cholesterol, resisting oxidation and the like can be prepared.
Abdominal aortic aneurysms (AAAs) are prevalent with aging, and AAA rupture is associated with increased mortality. There is currently no effective medical therapy to prevent AAA rupture. The monocyte chemoattractant protein (MCP-1)/C-C chemokine receptor type 2 (CCR2) axis critically regulates AAA inflammation, matrix-metalloproteinase (MMP) production, and extracellular matrix (ECM) stability. We therefore hypothesized that a diet intervention that can modulate CCR2 axis may therapeutically impact AAA risk of rupture. Since ketone bodies (KBs) can trigger repair mechanisms in response to inflammation, we evaluated whether systemic ketosis in vivo could reduce CCR2 and AAA progression. Male Sprague-Dawley rats underwent surgical AAA formation using porcine pancreatic elastase and received daily β-aminopropionitrile to promote AAA rupture. Rats with AAAs received either a standard diet, ketogenic diet (KD), or exogenous KBs (EKB). Rats receiving KD and EKB reached a state of ketosis and had significant reduction in AAA expansion and incidence of rupture. Ketosis also led to significantly reduced aortic CCR2 content, improved MMP balance, and reduced ECM degradation. Consistent with these findings, we also observed that Ccr2-/- mice have significantly reduced AAA expansion and rupture. In summary, this study demonstrates that CCR2 is essential for AAA expansion, and that its modulation with ketosis can reduce AAA pathology. This provides an impetus for future clinical studies that will evaluate the impact of ketosis on human AAA disease.
PURPOSE: A chitin bead with a uniform fine particle size being composed of microsporidian spores containing chitin as a major cell wall constituent, a chitosan bead with a uniform fine particle size being obtained by N-deacetylating the chitin, and a manufacturing method for the bead are provided. CONSTITUTION: Chitin beads having a uniform fine particle size and made of microsporidian spores containing chitin as the major cell wall constituent; and chitosan beads having a uniform fine particle size and obtained by N-deacetylating the chitin. Microsporidian spores are proliferated in insects or cultured cells to give the chitin beads. The chitosan beads are obtained by N-deacetylating the chitin. When the insects are domesticated silkworm larvae, 5 x 102 to 5 x 108/ml of microsporidian spores are orally or percutaneously inoculated into the larvae of second-instar exuviated domesticated silkworm and proliferated therein. Then the spores thus proliferated are taken out of the larvae of fifth-instar domesticated silkworm and purified to give chitin beads with a uniform small particle size. These beads are used as carriers for immobilizing or encapsulating various substances such as antibiotics and microorganisms therein.
PURPOSE: To provide a skin cosmetic containing a benzoic acid anilide compound and effective for suppressing the wrinkling and pigmentation of the skin. CONSTITUTION: This cosmetic contains a compound of formula (R<1> is H or t-butyl; R<2> is H, a 1-5C alkyl or an acyl) or its salt as an active component in an amount of 0.001-20wt.%, preferably 0.05-5wt.%. The suppression effect on the wrinkle and spots can be improved by incorporating the cosmetic with other conventional anti-inflammatory agent (e.g. allantoin), an antioxidant, etc. It can be prepared in the form of an O/W-type or W/O-type emulsified cosmetic, cream, cosmetic milky lotion, face lotion, oily cosmetic, pack, foundation, etc., by properly compounding with conventional cosmetic components. An example of the compound of formula is 4-hydroxy-N-(2-hydroxyphenyl) benzoic acid amide.
This is a Phase 1, open label, multicenter study to evaluate Claudin 18.2-targeting CAR-T cells (LB1908) in adult subjects with unresectable, locally advanced or metastatic gastric, GEJ, esophageal, or pancreatic adenocarcinoma. Patients will be confirmed to have sufficient expression of Claudin 18.2 as part of a prescreening. The study comprises a dose-escalation component (Part A) and a dose-expansion component (Part B). In part A, patients with gastric, GEJ, or esophageal adenocarcinoma will be treated with LB1908 at protocol-defined dose level, with escalation to higher doses in subsequent patients guided by evaluation of protocol-defined dose limiting toxicities (DLTs). Part A will identify the recommended dose for expansion (RDE) to be tested in part B in two cohorts: a gastric, GEJ and esophageal adenocarcinoma cohort as well as a pancreatic adenocarcinoma cohort. Part B will aim to identify the recommended dose for phase 2 (RP2D).
Indicators that can guide clinical decisions in cancer, particularly posttranslational modification of proteins which result in altered prognosis and differential sensitivity to targeted cancer therapy, are provided. In particular, monitoring of phosphorylation of PTEN may be utilized to predict or assess drug response, drug sensitivity, and clinical outcome. Modulation of PTEN phosphorylation may be utilized to alter sensitivity and outcome in cancer patients. Posttranslational modification of PTEN, particularly phosporylation, is correlated with resistance to targeted cancer therapy, including EGFR inhibitors, and with reduced survival prognosis. Methods and assays for determining phosphorylation of PTEN, particularly Y240 phosphorylation, are provided. Methods for sensitizing tumors to inhibition and targeted therapy by modulating PTEN phosphorylation are provided.
Atrial fibrillation (AF) is the most frequent type of cardiac arrhythmia that affects over six million individuals in Europe. The incidence and prevalence of AF rises with age, and often occurs after cardiac surgery. Other risk factors correlated with AF comprise high blood pressure, diabetes mellitus, left atrial enlargement, ischemic heart disease, and congestive heart failure. Considering the high prevalence of AF in aging societies, strategies to prevent serious complications, such as stroke or heart failure, are important because they are correlated with high morbidity and mortality. The supplementation of sea-derived n-3 polyunsaturated fatty acids (PUFA) is widely discussed in this context, but the results of experimental and observational studies are in contrast to randomized placebo-controlled intervention trials (RCTs). Specifically, larger placebo-controlled n-3 PUFA supplementation studies with long follow-up showed a dose-dependent rise in incident AF. Daily n-3 PUFA doses of ≥1 g/d are correlated with a 50 % increase in AF risk, whereas a daily intake of <1 g/d causes AF in only 12 %. Individuals with a high cardiovascular risk (CVD) risk and high plasma-triglycerides seem particularly prone to develop AF upon n-3 PUFA supplementation. Therefore, we should exercise caution with n-3 PUFA supplementation especially in patients with higher age, CVD, hypertriglyceridemia or diabetes. In summary, existing data argue against the additive intake of n-3 PUFA for preventative purposes because of an incremental AF risk and lacking CVD benefits. However, more clinical studies are required to disentangle the discrepancy between n-3 PUFA RCTs and observational studies showing a lower CVD risk in individuals who regularly consume n-3 PUFA-rich fish.
AIM: The hypothesis of this study is to determine the effects of intracerebroventricular (icv) prokineticin 2 infusion on food consumption and body weight and to elucidate whether it has effects on energy expenditure via the hypothalamus-pituitary-thyroid (HPT) axis in adipose tissue.
MATERIAL AND METHODS: A total of 40 rats were used in the study and 4 groups were established: Control, Sham, Prokineticin 1.5 and Prokineticin 4.5 (n=10). Except for the Control group, rats were treated intracerebroventricularly via osmotic minipumps, the Sham group was infused with aCSF (vehicle), and the Prokineticin 1.5 and Prokineticin 4.5 groups were infused with 1.5 nMol and 4.5 nMol prokineticin 2, respectively. Food and water consumption and body weight were monitored during 7-day infusion in all groups. At the end of the infusion, the rats were decapitated and serum TSH, fT4 and fT3 levels were determined by ELISA. In addition, PGC-1α and UCP1 gene expression levels in white adipose tissue (WAT) and brown adipose tissue (BAT), TRH from rat hypothalamic tissue were determined by real-time PCR.
RESULTS: Icv prokineticin 2 (4.5 nMol) infusion had no effect on water consumption but reduced daily food consumption and body weight (p<0.05). Icv prokineticin 2 (4.5 nMol) infusion significantly increased serum TSH, fT4 and fT3 levels when compared to Control and Sham groups (p<0.05). Also, icv prokineticin 2 (4.5 nMol) infusion increased the expression of TRH in the hypothalamus tissue and expression of PGC-1α UCP1 in the WAT and BAT (p<0.05).
CONCLUSION: Icv prokineticin 2 (4.5 nMol) infusion may suppress food consumption via its receptors in the hypothalamus and reduce body weight by stimulating energy expenditure and thermogenesis in adipose tissue through the HPT axis.
All the selected 20 healthy subjects will undergo the radial pressure waves treatment on one leg at the Gastrocnemius, left or right leg as per randomization. Afterwards each patient will undergo NMES electrostimulation treatment on the opposite leg at the Gastrocnemius.
Research indicates that AAC (Augmentative and Alternative Communication) has the potential to change the lives of many people with complex communication needs, but is often under-utilised and/or abandoned. Therefore, the research aims to investigate the meaning, value, and purpose of AAC for different stakeholder groups, as well as to what extent these are shared or unique? This information will support Speech and Language Therapists to understand the meaning, value, and purpose of AAC for key stakeholders, and therefore adapt intervention to meet these needs. It can also support families considering AAC in decision making. Participants can also benefit through reflecting on what AAC means to them. It is also an important part of evidence based practice to listen to the voice of the client and family.

A qualitative descriptive study is proposed, utilising thematic analysis. The study will be implemented using a survey which will be presented in different formats (paper/online/face-to-face) depending on the stakeholder. It will investigate the perceptions of people who use AAC, family members, teaching staff and health professionals who work with AAC users. Family members, adult AAC users, teachers and health professionals will receive a link to an online survey, distributed by professional groups and charities. Parents of children attending local special schools will be given paper copies of the survey. Face to face interviews with up to 5 children who use AAC will also be carried out at local special schools, following consent from the parents. Interviews will be conducted by a trained Speech and Language Therapist using symbols to support communication via a Talking Mats style approach,and children will be accompanied by an adult. It is estimated that interviews will last between 20 and 30 minutes.

Participants filling in the paper or online survey are encouraged to write as much or as little as they like; it is estimated that it will take around 10 minutes to complete, although others may spend longer.
BACKGROUND: The advent of advanced computed tomography (CT) technology and the field of radiomics has opened up new avenues in diagnostic assessments. Increasingly, there is substantial evidence advocating for the incorporation of quantitative imaging biomarkers in the clinical decision-making process. This study aimed to examine the correlation between D-dimer levels and thrombus size in acute pulmonary embolism (PE) combining dual-energy CT (DECT) and radiomics and to investigate the diagnostic utility of a machine learning classifier based on dual-energy computed tomography (DECT) radiomics for identifying patients with a complicated course, defined as at least hospitalization at IMC.
METHODS: The study was conducted including 136 participants who underwent pulmonary artery CT angiography from January 2015 to March 2022. Based on DECT imaging, 107 radiomic features were extracted for each patient using standardized image processing. After dividing the dataset into training and test sets, stepwise feature reduction based on reproducibility, variable importance and correlation analyses were performed to select the most relevant features; these were used to train and validate the gradient-boosted tree models.Receiver operating characteristics (ROC) analysis was utilized to evaluate the association between volumetric, laboratory data and adverse outcomes.
RESULTS: In the central PE group, we observed a significant correlation between thrombus volumetrics and D-dimer levels (p = 0.0037), as well as between thrombus volumetrics and hospitalization at the Intermediate Care Unit (IMC) (p = 0.0001). In contrast, no statistically significant differences were identified in thrombus sizes between patients who experienced complications and those who had a favorable course (p = 0.3162). The trained machine learning classifier achieved an accuracy of 61% and 55% in identifying patients with a complicated course, as indicated by an area under the ROC curve of 0.63 and 0.58.
CONCLUSION: In conclusion, our findings indicate a positive correlation between D-dimer levels and central PE's pulmonary embolic burden. Thrombus volumetrics may serve as an indicator for complications and outcomes in acute PE patients. Thus, thrombus volumetrics, as opposed to D-dimers, could be an additional marker for evaluating embolic disease severity. Moreover, DECT-derived radiomic feature models show promise in identifying patients with a complicated course, such as hospitalization at IMC.
The goal of this study is to test whether providing hearing assistance devices to older age hearing impaired patients in the ED setting will improve in-ED understanding and preparation for discharge. The proposed intervention, the Hearing Impairment, Strategies and Outcomes in VA Emergency Departments (HearVA-ED) will be conducted in the Emergency Departments of the Manhattan and Brooklyn VAs of the New York Harbor Healthcare System and will recruit hearing impaired ED patients who are 60 years and older and have been admitted to the ED with a low acuity triage score indicating a high likelihood of discharge home. The investigators will identify hearing impairment by using the Hearing Handicap Inventory for the Elderly survey (HHIE-S). The investigators will randomize consenting patients who fail the screening to either receipt of a simple hearing assistance device (a "PockeTalkerTM") during their ED stay or usual care. The investigators will test whether the provision of a PockeTalkerTM is feasible in this environment (by measuring the amount of device use), whether providing the device improves self-reported quality of hearing and understanding during the ED stay, and whether use of the device improves the quality of preparation for post-discharge care. If this randomized controlled trial demonstrates beneficial effects for in-ED use of a simple hearing assistance device for hearing impaired patients, this strategy can be disseminated throughout the VA healthcare system.
Disclosed herein are vectors for delivering nucleic acid sequences into target cells. The vector is a non-viral DNA construct. The vector has at least one DD-ITR and a complementary copy of a nucleic acid sequence operably linked to regulatory elements that facilitate expression. The construct has covalently closed ends with hairpin structures and persists in the recipient cell as it divides. Delivery of the vector to the target cell results in sustained expression of the nucleic acid sequence in the target cell. Also disclosed are DNA vector constructs having at least one synthetic ITR, wherein the DNA construct forms a linear DNA with hairpin covalently closed ends. Also disclosed are methods of producing the constructs and introducing into target cells to facilitate sustained expression of the nucleic acid sequences contained therein. Further disclosed are cells and populations thereof comprising the vectors.
This was a randomized (the study drug is assigned by chance) and open labeled (all people know the identity of the intervention) study. All participants were hospitalized in research rooms and were subsequently restricted in exercise, eating, drinking, smoking and xanthine-beverages until the end of blood collection. Water was allowed to be taken until one hour before drug administration. Participants were randomly assigned into two groups, one group receiving Risperdal OD (investigational drug), and one group receiving Risperdal Quicklet (control drug). On the day of testing, blood was collected from all participants to provide baseline measurements. Subsequently, the study drug was orally administered to the participants, followed by blood collection of a total of 13 time points, up to 24 hours. After the blood collection was finished, participants were discharged after receiving proper guidance and being examined by a psychologist. Following a wash-out period (period when receiving no intervention) of one week, participants were hospitalized once more and crossed over to receive the study drugs following the same procedure above described. The approximate study duration (including the drug administration days and wash-out period) was approximately 10 days.